A New Galloylglucoside from *Cleyera ochnacea* DC.

Tsuneo Iwakawa,* Yoshimi Tanaka, and Akira Takashima

Aburahi Laboratories, Shionogi & Co., Ltd., Koka, Shiga 520–3423, Japan. Received June 29, 2001; accepted September 1, 2001

A new galloylglucoside, 3-hydroxy-5-methylphenol $1-O-\beta$ -D-(6'-galloyl)glucopyranoside (1) was isolated from *Cleyera ochnacea* DC. (Theaceae). Its structure was elucidated on the basis of chemical and spectral analysis. Compound 1 showed inhibitory activity against rat cerebellar nitric oxide synthase (NOS).

Key words galloylglucoside; nitric oxide synthase (NOS); Cleyera ochnacea DC.

Cleyera ochnacea DC. (Theaceae) (Japanese name: Sakaki) is a small evergreen tree. This tree is common in the forests of southwestern Japan up to 1400 m elevation,¹⁾ and it has been traditionally reserved for Shinto-shrine worship. The chemical constituents of the plant have been investigated, and acids and glucosides have been isolated.^{2,3)} As part of our continuous search for novel biologically active compounds from plants, crude extract of *C. ochnacea* DC. was found to show inhibitory activity against rat cerebellar nitric oxide synthase (NOS). Bioactivity-guided chromatographic fractionation of the active extract led to the isolation and characterization of a new compound, 3-hydroxy-5-methylphenol 1-*O*- β -D-(6'-galloyl)glucopyranoside. Herein, we repound and its inhibitory activity against rat cerebellar NOS.

The MeOH extract of *C. ochnacea* DC. was suspended in water and then extracted with AcOEt and *n*-BuOH, successively. The *n*-BuOH extract was treated as described in Experimental to isolate compound **1**.

Compound 1, obtained as an off-white amorphous powder, $[\alpha]_D - 20.3^{\circ}C$ (MeOH), gave a positive response to the ferric chloride reagent, and its molecular formula was established as $C_{20}H_{22}O_{11}$ by high resolution (HR)-FAB-MS. The liquid secondary ion (LSI)-MS of 1 exhibited an $[M+H]^+$ ion peak at m/z 439, together with a minor peak at m/z 153, suggestive of the presence of a galloyl group. This was supported by a two-proton singlet at δ 7.10 in the ¹H-NMR spectrum and



Fig. 1. HMBC Correlations for Compound 1

five characteristic carbon signals (δ 166.7, 146.1, 138.8, 121.7, 110.0) in the ¹³C-NMR spectrum. The remaining 13 signals indicated one methyl (δ 21.5) and six aromatic (δ 159.9, 158.9, 140.8, 111.0, 109.3, 102.2) carbons, as well as six carbons corresponding to a glucose moiety (δ 101.9, 77.8, 75.1, 74.7, 71.2, 64.4). The configuration of the anomeric center in the glucose moiety was assigned as β from coupling constant (J=7.5 Hz) of the anomeric proton in the ¹H-NMR spectrum. The ¹H- and ¹³C-NMR data of **1** were similar to those of 3-hydroxy-5-methoxylphenol 1-O- β -D-(6'-galloyl)glucopyranoside except for some signals assignable to the 5-methoxyresorcinol moiety.⁴⁾ The ¹H-NMR spectrum of 1 showed an aromatic methyl group (δ 2.08, 3H, s) and three aromatic protons [(δ 6.26, 1H, br s), (δ 6.35, 2H, brs)], indicative of a 5-methylresorcinol. In addition, the LSI-MS data of 1 showed a fragment ion peak at m/z 315, which was derived by elimination of the 3-hydroxy-5methylphenoxy group.

This was confirmed by enzymatic hydrolysis. Treatment of **1** with β -glucosidase gave the aromatic compound (2). Compound **2** was identified as 5-methylresorcinol by comparison with the ¹H- and ¹³C-NMR spectrum of an authentic sample.

The connections between the above units were assigned on the basis of ${}^{1}\text{H}{-}{}^{13}\text{C}$ long-range correlations in the heteronuclear multiple bond connectivity (HMBC) spectrum. (Fig. 1) HMBC showed correlations of the anomeric proton (δ 4.89) to C-1 of the 5-methylresorcinol moiety (δ 159.9), and 6'-H₂ of the β -glucose moiety (δ 4.32, 4.56) to the ester carbonyl carbon of the gallic acid moiety (δ 166.7), indicating the location of the β -glucose and gallic acid moieties to be at C-1 and C-6', respectively. Thus, compound 1 was determined to be 3-hydroxy-5-methylphenol 1-O- β -D-(6'-galloyl)glucopyranoside.

Inhibitory activity of **1** against inducible NOS (iNOS) and neuronal NOS (nNOS) was evaluated according to the methods in the indicated references.^{5,6)} The IC₅₀ values of reference compound, $N^{\rm G}$ -monomethyl-L-arginine,⁷⁾ were 10.0 μ M for iNOS and 1.1 μ M for nNOS. Compound **1** showed weak inhibitory activity; its IC₅₀ values were 152 μ M for iNOS and 515 μ M for nNOS.

Experimental

General Procedures Optical rotation was recorded on a Perkin-Elmer 241 polarimeter. MS were obtained by use of a Hitachi M-90 (LSI-MS) or a JEOL JMS-SX/SX102A (HR-FAB-MS) mass spectrometer. One- and two-dimensional (1D, 2D) NMR spectra were measured with a JEOL JNM A-400 spectrometer. Chemical shifts were expressed in ppm downfield from internal tetramethylsilane. Chromatorex (Fuji Silysia Chemical Ltd.) was used for column chromatography. Precoated silica gel Kieselgel 60 F_{254} plates (0.25 mm thickness) were used for TLC, and the spots were detected

by spraying with 1% $Ce(SO_4)_2/10\%$ H₂SO₄, followed by heating. Preparative HPLC was carried out on a Develosil ODS 10/20 column (i.d. 20 mm×250 mm) and guard column (i.d. 20 mm×50 mm) (Nomura Chemical) with detection by UV absorption at 220 nm (Shinadzu SPD 6A).

Plant Material The plant material *Cleyera ochnacea* DC. was collected from the botanical garden of Aburahi Laboratories, Shionogi & Co., Ltd. in January 1996.

Extraction and Isolation Fresh leaves and branches (1.2 kg) were chopped into small pieces and extracted twice with MeOH at room temperature for 7 d. Then the extract was evaporated *in vacuo* to yield the MeOH extract (93.7 g). The MeOH extract (20 g) was then suspended in distilled water and successively extracted with AcOEt, *n*-BuOH. The *n*-BuOH soluble fraction was evaporated under reduced pressure to give brown oil (8.1 g). The *n*-butanol-soluble fraction (1.0 g) was subjected to Chromators (ODS) column chromatograph with H₂O–MeOH (80:20 \rightarrow 0:100) to afford four fractions. Fraction 2 (228 mg) was subjected to HPLC (ODS) (CH₃CN : H₂O=20:80) to give 1 (45 mg).

3-Hydroxy-5-methylphenol 1-*O*- β -D-(6'-Galloyl)glucopyranoside (1) An off-white amorphous powder, $[\alpha]_{26}^{26} - 20.3^{\circ}$ (c=0.22, MeOH). LSI-MS m/z (rel. int. %): 439 (M+H, 48), 341 (65), 315 (70), 219 (100), 153 (70). HR-FAB-MS m/z: 439.1243 [M+H]⁺ (Calcd for C₂₀H₂₃O₁₁, 439.1240). ¹H-NMR (400 MHz, acetone- d_6) δ : 2.08 (3H, s, Me-5), 3.40—3.54 (3H, m, H-2', 3', 4'), 3.77 (1H, m, H-5'), 4.32 (1H, dd, J=6.1, 11.7 Hz, H-6'a), 4.56 (1H, dd, J=2.0, 11.7 Hz, H-6'b), 4.89 (1H, d, J=7.5 Hz, H-1'), 6.26 (1H, br s, H-4), 6.35 (2H, br s, H-2, 6), 7.10 (2H, s, H-2", 6"). ¹³C-NMR (100 MHz, acetone- d_6) δ : 21.5 (q, Me), 64.4 (t, C-6'), 71.2 (d, C-4'), 74.7 (d, C-2'), 75.1 (d, C-5'), 77.8 (d, C-3'), 101.9 (d, C-1'), 102.2 (d, C-2), 109.3 (d, C-6), 110.0 (d, 2C, C-2", 6"), 111.0 (d, C-4) 121.7 (s, C-1"), 138.8 (s, C-4"), 140.8 (s, C-5), 146.1 (s, 2C, C-3", 5"), 158.9 (s, C-3), 159.9 (s, C-1), 166.7 (s, CO).

Enzymatic Hydrolysis of 1 Compound **1** (60 mg) and β -glucosidase (SIGMA G-0395, 120 mg) were suspended in 0.1 M acetate buffer (pH 5.0, 24 ml) and incubated at 37°C for 24 h. The reaction mixture was extracted with Et₂O (20 ml×2) and the organic layer was dried and further evaporated to dryness. The Et₂O extract (12 mg) was subjected to chromatography on silica gel (*n*-hexane: AcOEt=2:3) to obtain 5-methylresorcinol (6 mg).

Acknowledgments We are grateful to Dr. Masafumi Fuzimoto, Director of Aburahi Laboratories of Shionogi & Co., for his encouragement and permission to publish this work. We also wish to express our thanks to Professor Isao Kitagawa (Kinki University, Osaka) for discussions and helpful support.

References

- Horikawa Y., "Atlas of the Japanese Flora," Gakken Co., Ltd., Tokyo, 1972, p. 218.
- 2) Ueda J., Kato J., Agric. Biol. Chem., 46, 1975-1976 (1982).
- Yamada T., Tanaka H., Aoki H., Namiki M., Agric. Biol. Chem., 32, 599–604 (1968).
- 4) Andreas D., Frank P., Adorf N., Phytochemistry, 37, 533-538 (1994).
- Matumoto T., Pollock J. S., Nakane M., Forstermann U., Developmental Brain Research, 73, 199–203 (1993).
- Moor P. K., Babbedge R. C., Wallace P., Gaffen Z. A., Hart S. L., *Br. J. Pharmacol.*, **108**, 296–297 (1993).
- Rees D. D., Palmer R. M., Schlz R., Hodson H. F., Monacada S., *Br. J. Pharmacol.*, 101, 746–752 (1990).